The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
Launched by KIRBY INSTITUTE · Feb 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The National Australian HCV Point-of-Care Testing Program is a study aimed at improving how we screen for and treat Hepatitis C, a virus that affects the liver. The researchers want to find out if using a quick test that can be done on-site (like a finger-prick test) can help identify more people who might be infected with Hepatitis C. They will look at how many participants diagnosed with the virus start treatment within 12 weeks after being diagnosed.
Adults aged 18 and older who are at risk for Hepatitis C can join the study. During a single visit, participants will give their consent and undergo a quick test for Hepatitis C. If the test shows they might be infected, they will receive further tests to confirm the diagnosis. However, this study does not provide treatment; instead, participants who are found to have Hepatitis C will be referred to other healthcare providers for the necessary care. It’s an important step towards improving Hepatitis C detection and treatment in the community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provide informed consent
- • ≥ 18 years of age.
- Exclusion Criteria:
- • Is unable or unwilling to provide informed consent
About Kirby Institute
The Kirby Institute is a leading research organization based at the University of New South Wales (UNSW) in Australia, dedicated to advancing global health through innovative clinical research, particularly in the fields of infectious diseases, HIV, and public health. With a strong emphasis on collaboration, the Institute conducts rigorous clinical trials and epidemiological studies, translating scientific findings into effective health policies and practices. Its multidisciplinary team of researchers, clinicians, and public health experts works to improve health outcomes and inform treatment strategies, making significant contributions to both local and international health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Sydney, New South Wales, Australia
Cairns, Queensland, Australia
Woodford, Queensland, Australia
Canberra, Australian Capital Territory, Australia
Brisbane, Queensland, Australia
Adelaide, South Australia, Australia
Bowen Hills, Queensland, Australia
Townsville, Queensland, Australia
Hackney, South Australia, Australia
Hobart, Tasmania, Australia
Perth, Western Australia, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials